XML 37 R23.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Accrued Expenses and Other Current Liabilities | 12 Months Ended
--- | ---
Dec. 31, 2023
Payables and Accruals [Abstract] |
Accrued Expenses and Other Current Liabilities | ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following (in thousands):
| December 31,
| 2023 |  | 2022
Accrued payments due to AstraZeneca | $ | 3,680 |  |  | $ | 3,385 |
Accrued gross to net revenue liabilities | 3,258 |  |  | 1,991 |
Accrued contract manufacturing expenses | 1,946 |  |  | 1,657 |
Accrued sales and marketing expenses | 3,223 |  |  | 587 |
Accrued professional and consulting services | 486 |  |  | 808 |
Derivative liability for exit fees | 675 |  |  | 1,656 |
Accrued clinical expenses | 377 |  |  | 223 |
Accrued non-clinical research and development expenses | 30 |  |  | 1,188 |
Other | 1,366 |  |  | 885 |
Total accrued expenses and other current liabilities | $ | 15,041 |  |  | $ | 12,380 |

X
- Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + References No definition available. + Details
Name: | us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration